MedTrace Logo

AL-15469A for the Treatment of Bacterial Conjunctivitis

NCT00332293 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 695

Last updated 2016-11-18

No results posted yet for this study

Summary

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.

Conditions

  • Bacterial Conjunctivitis

Interventions

DRUG

Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%

1 drop into the conjunctival sac of both eyes 3 times a day for 3 days

DRUG

Moxifloxacin hydrochloride ophthalmic solution 0.5% as base

1 drop into the conjunctival sac of both eyes 3 times a day for 3 days

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
1 Month
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00332293 on ClinicalTrials.gov